The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
Abstract
Fluctuations in the symptoms of Parkinson's disease (PD), such as wearing-off and on-off effects, and dyskinesias are related to a variety of factors, including duration and dosage of levodopa, age at onset, stress, sleep, food intake, and other pharmacokinetic and pharmacodynamic mechanisms. The majority of patients, particularly those with young onset of PD, experience these levodopa-related adverse effects after a few years of treatment. Assessment of these motor complications is difficult because of the marked clinical variability between and within patients. Daily diaries have been used in clinical trials designed to assess the effects of various pharmacological and surgical interventions on motor fluctuations and dyskinesias. The most common type of dyskinesia, called "peak-dose dyskinesia", usually consists of stereotypical choreic or ballistic movements involving the head, trunk, and limbs, and occasionally, the respiratory muscles, whereas tremor and punding are less-common complications. Dystonia is also typically seen in patients with diphasic dyskinesia and wearing-off effect. Recognition of the full spectrum of clinical phenomenology of levodopa-related motor complications is essential for their treatment and prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10720 · Cited by 1,307
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fenelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,037
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Dyskinesias and motor fluctuations in Parkinson's disease
Schrag, A., & Quinn, N. (2000) · Brain · doi:10.1093/brain/123.11.2297 · Cited by 600
Giovannoni, G. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.4.423 · Cited by 587
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Parkin disease: a phenotypic study of a large case series
Khan, N. L., Graham, E., Critchley, P., Schrag, A. E., Wood, N. W., Lees, A. J., Bhatia, K. P., & Quinn, N. (2003) · Brain · doi:10.1093/brain/awg142 · Cited by 352
Cited by
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Technology in Parkinson’s disease: challenges and opportunities
Espay, A. J., Bonato, P., Nahab, F. B., Maetzler, W., Dean, J. M., Klucken, J., Eskofier, B. M., Merola, A., Horak, F., Lang, A. E., et al. (2016) · Movement Disorders · doi:10.1002/mds.26642 · Cited by 654
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Molecular mechanisms of L-DOPA-induced dyskinesia
Jenner, P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2471 · Cited by 523
Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., & Goetz, C. G. (2007) · Movement Disorders · doi:10.1002/mds.21475 · Cited by 464
Advances in the treatment of Parkinson's disease
Singh, N., Pillay, V., & Choonara, Y. E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.009 · Cited by 394
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
Current approaches to the treatment of Parkinson’s disease
Jankovic, J. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2006 · Cited by 342
Self-citationHorstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease
Church, F. C. (2021) · Biomolecules · doi:10.3390/biom11040612 · Cited by 290
Clinical spectrum of levodopa‐induced complications
Aquino, C. C., & Fox, S. H. (2015) · Movement Disorders · doi:10.1002/mds.26125 · Cited by 270
Goetz, C. G., Damier, P., Hicking, C., Laska, E., Müller, T., Olanow, C. W., Rascol, O., & Russ, H. (2007) · Movement Disorders · doi:10.1002/mds.21226 · Cited by 260
Lonini, L., Dai, A., Shawen, N., Simuni, T., Poon, C., Shimanovich, L., Daeschler, M., Ghaffari, R., Rogers, J. A., & Jayaraman, A. (2018) · npj Digital Medicine · doi:10.1038/s41746-018-0071-z · Cited by 209
Mahadevan, N., Demanuele, C., Zhang, H., Volfson, D., Ho, B., Erb, M. K., & Patel, S. (2020) · npj Digital Medicine · doi:10.1038/s41746-019-0217-7 · Cited by 138
Bordia, T., Campos, C., Huang, L., & Quik, M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140897 · Cited by 120
Ultrasound targeted CNS gene delivery for Parkinson's disease treatment
Fan, C.-H., Lin, C.-Y., Liu, H.-L., & Yeh, C.-K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.004 · Cited by 97
Higher iron in the red nucleus marks Parkinson's dyskinesia
Lewis, M. M., Du, G., Kidacki, M., Patel, N., Shaffer, M. L., Mailman, R. B., & Huang, X. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.025 · Cited by 84
Clinical implications of gastric complications on levodopa treatment in Parkinson’s disease
Pfeiffer, R. F., Isaacson, S. H., & Pahwa, R. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.05.001 · Cited by 77
Khatri, D. K., Preeti, K., Tonape, S., Bhattacharjee, S., Patel, M., Shah, S., Singh, P. K., Srivastava, S., Gugulothu, D., Vora, L., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x20666220507022701 · Cited by 75
Mera, T. O., Burack, M. A., & Giuffrida, J. P. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-120166 · Cited by 66
“the drug dose required for motor benefit increases; however, the threshold for manifestation of dyskinesia decreases [1, 2].”
Liu, H., Su, W., Li, S., Du, W., Ma, X., Jin, Y., Li, K., & Chen, H. (2017) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2017.07.003 · Cited by 43
Metadata
- Authors
- Jankovic, J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2005
- Volume
- 20
- Issue
- S11
- Pages
- S11-S16
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2014583561
- Cited by
- 547
- References
- 55
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.